Triamcinolone
Aristocort, Kenacort, Kenalog, Myco-triacet, Mycolog-ii, Mytrex, Nasacort, Triesence, Xipere, Zilretta (triamcinolone) is a small molecule pharmaceutical. Triamcinolone was first approved as Aristocort on 1982-01-01. It is used to treat adrenal insufficiency, allergic rhinitis perennial, ankylosing spondylitis, atopic dermatitis, and berylliosis amongst others in the USA. The pharmaceutical is active against glucocorticoid receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
infections | D007239 |
musculoskeletal diseases | D009140 |
digestive system diseases | D004066 |
respiratory tract diseases | D012140 |
otorhinolaryngologic diseases | D010038 |
nervous system diseases | D009422 |
eye diseases | D005128 |
urogenital diseases | D000091642 |
hemic and lymphatic diseases | D006425 |
hereditary congenital and neonatal diseases and abnormalities | D009358 |
Show 7 more
Trade Name
FDA
EMA
Kenalog, Nasacort, Triesence, Xipere, Zilretta (generic drugs available since 1982-01-01, discontinued: Allernaze, Aristocort, Aristocort a, Aristogel, Azmacort, Flutex, Kenacort, Oralone, Triacet, Triacort, Triatex, Trivaris, Trymex)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Triamcinolone
Triamcinolone acetonide
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
KENALOG-10 | Bristol Myers Squibb | N-012041 RX | 1982-01-01 | 1 products, RLD |
KENALOG-80 | Bristol Myers Squibb | N-014901 RX | 2019-04-12 | 1 products, RLD, RS |
KENALOG-40 | Bristol Myers Squibb | N-014901 RX | 1982-01-01 | 1 products, RLD, RS |
XIPERE | Bausch Health Companies | N-211950 RX | 2021-10-22 | 1 products, RLD, RS |
NASACORT ALLERGY 24 HOUR | Sanofi | N-020468 OTC | 2013-10-11 | 1 products, RLD, RS |
TRIESENCE | Novartis | N-022048 RX | 2007-11-29 | 1 products, RLD, RS |
ZILRETTA | Pacira BioSciences | N-208845 RX | 2017-10-06 | 1 products, RLD, RS |
KENALOG | Sun Pharmaceutical Industries | N-012104 RX | 1982-01-01 | 1 products, RLD, RS |
Show 10 discontinued
Triamcinolone diacetate
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
allernaze | New Drug Application | 2010-11-23 |
lidolog kit | unapproved drug other | 2023-05-15 |
nasacort allergy 24hr | New Drug Application | 2022-04-20 |
oralone | ANDA | 2019-01-14 |
triamcinolone acetonide | ANDA | 2023-06-19 |
trianex 0.05% | ANDA | 2021-05-12 |
triderm | ANDA | 2023-02-13 |
triesence | New Drug Application | 2020-10-02 |
xipere | New Drug Application | 2021-10-25 |
xuriden | New Drug Application | 2019-12-16 |
Show 1 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
adrenal insufficiency | — | D000309 | — |
allergic rhinitis perennial | EFO_1001417 | D012221 | J30.89 |
ankylosing spondylitis | EFO_0003898 | D013167 | M45 |
atopic dermatitis | EFO_0000274 | D003876 | L20 |
berylliosis | EFO_0007168 | D001607 | J63.2 |
bronchial spasm | — | D001986 | — |
dermatitis herpetiformis | — | D003874 | L13.0 |
erythema multiforme | — | D004892 | L51 |
facial dermatoses | — | D005148 | — |
foot dermatoses | — | D005533 | — |
Show 17 more
Agency Specific
FDA
EMA
Expiration | Code | ||
---|---|---|---|
TRIAMCINOLONE ACETONIDE, XIPERE, BAUSCH AND LOMB INC | |||
2024-10-22 | NP |
Patent Expiration
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Triamcinolone Acetonide, Xipere, Bausch And Lomb Inc | |||
9937075 | 2034-05-02 | DP | |
9636332 | 2033-11-08 | U-3234 | |
8636713 | 2027-05-02 | U-3234 | |
Triamcinolone Acetonide, Zilretta, Pacira Pharms Inc | |||
8828440 | 2031-08-04 | DP | |
9555048 | 2031-08-04 | U-2151 | |
Triamcinolone Acetonide, Triesence, Novartis | |||
8128960 | 2029-12-17 | DP | |
8211880 | 2029-03-10 | U-1257, U-1258 |
ATC Codes
A: Alimentary tract and metabolism drugs
— A01: Stomatological preparations
— A01A: Stomatological preparations
— A01AC: Corticosteroids for local oral treatment
— A01AC01: Triamcinolone
C: Cardiovascular system drugs
— C05: Vasoprotectives
— C05A: Agents for treatment of hemorrhoids and anal fissures for topical use
— C05AA: Corticosteroids, topical for treatment of hemorrhoids and anal fissures
— C05AA12: Triamcinolone
D: Dermatologicals
— D07: Corticosteroids, dermatological preparations
— D07A: Corticosteroid dermatological preparations, plain
— D07AB: Corticosteroids, moderately potent (group ii)
— D07AB09: Triamcinolone
— D07B: Corticosteroids, combinations with antiseptics
— D07BB: Corticosteroids, moderately potent, combinations with antiseptics
— D07BB03: Triamcinolone and antiseptics
— D07C: Corticosteroids, combinations with antibiotics
— D07CB: Corticosteroids, moderately potent, combinations with antibiotics
— D07CB01: Triamcinolone and antibiotics
— D07X: Corticosteroids, other combinations
— D07XB: Corticosteroids, moderately potent, other combinations
— D07XB02: Triamcinolone
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H02: Corticosteroids for systemic use
— H02A: Corticosteroids for systemic use, plain
— H02AB: Glucocorticoids, systemic
— H02AB08: Triamcinolone
R: Respiratory system drugs
— R01: Nasal preparations
— R01A: Decongestants and other nasal preparations for topical use
— R01AD: Corticosteroid nasal preparations for topical use
— R01AD11: Triamcinolone
— R03: Drugs for obstructive airway diseases
— R03B: Other drugs for obstructive airway diseases, inhalants in atc
— R03BA: Glucocorticoid inhalants for obstructive airway disease
— R03BA06: Triamcinolone
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01B: Antiinflammatory agents, ophthalmologic
— S01BA: Corticosteroid ophthalmologic antiinflammatory agents, plain
— S01BA05: Triamcinolone
— S02: Otologicals
— S02C: Corticosteroids and antiinfectives in combination, otologic
— S02CA: Corticosteroids and antiinfectives in combination
— S02CA04: Triamcinolone and antiinfectives
HCPCS
Code | Description |
---|---|
J3300 | Injection, triamcinolone acetonide, preservative free, 1 mg |
J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
J3302 | Injection, triamcinolone diacetate, per 5 mg |
J3303 | Injection, triamcinolone hexacetonide, per 5 mg |
J3304 | Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg |
J7683 | Triamcinolone, inhalation solution, compounded product, administered through dme, concentrated form, per milligram |
J7684 | Triamcinolone, inhalation solution, compounded product, administered through dme, unit dose form, per milligram |
Clinical
Clinical Trials
52 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Sleep initiation and maintenance disorders | D007319 | F51.01 | — | — | 3 | 2 | 3 | 8 | |
Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | 2 | 1 | 1 | 5 |
Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | 2 | 1 | — | 1 | 1 | 4 |
Delirium | D003693 | R41.0 | — | — | — | 2 | 1 | 3 | |
Sleep apnea syndromes | D012891 | EFO_0003877 | G47.3 | — | 1 | — | 2 | — | 3 |
Sleep wake disorders | D012893 | G47 | — | — | 2 | 1 | — | 3 | |
Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 1 | 1 | — | 2 |
Substance-related disorders | D019966 | EFO_0003890 | F13 | — | — | — | 1 | 1 | 2 |
Cognitive dysfunction | D060825 | G31.84 | — | — | — | 1 | 1 | 2 | |
Spinal cord injuries | D013119 | EFO_1001919 | — | 1 | — | 1 | — | 2 |
Show 5 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Depression | D003863 | F33.9 | 2 | 1 | 2 | — | 1 | 5 | |
Treatment-resistant depressive disorder | D061218 | — | — | 1 | — | 1 | 2 | ||
Alzheimer disease | D000544 | EFO_0000249 | F03 | — | — | 2 | — | — | 2 |
Dementia | D003704 | F03 | — | — | 1 | — | — | 1 | |
Psychophysiologic disorders | D011602 | F45.9 | — | — | 1 | — | — | 1 | |
Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | — | — | 1 |
Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | — | 1 | 1 | — | — | 1 |
Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | — | 1 | — | — | 1 |
Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | 1 | — | — | 1 |
Sleep | D012890 | GO_0030431 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Diabetic neuropathies | D003929 | EFO_1000783 | — | 2 | — | — | — | 2 | |
Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 1 | — | — | — | 1 |
Amnesia | D000647 | EFO_1001454 | F44.0 | — | 1 | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Wounds and injuries | D014947 | T14.8 | — | — | — | — | 1 | 1 | |
Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 1 | 1 |
Chronic disease | D002908 | — | — | — | — | 1 | 1 | ||
Brain injuries | D001930 | S06.9 | — | — | — | — | 1 | 1 | |
Alcohol-related disorders | D019973 | F10 | — | — | — | — | 1 | 1 | |
Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | — | — | — | 1 | 1 |
Suicidal ideation | D059020 | EFO_0004320 | R45.851 | — | — | — | — | 1 | 1 |
Sepsis-associated encephalopathy | D065166 | G93.41 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | TRIAMCINOLONE |
INN | triamcinolone |
Description | Triamcinolone is a C21-steroid hormone that is 1,4-pregnadiene-3,20-dione carrying four hydroxy substituents at positions 11beta, 16alpha, 17alpha and 21 as well as a fluoro substituent at position 9. Used in the form of its 16,17-acetonide to treat various skin infections. It has a role as an anti-allergic agent and an anti-inflammatory drug. It is a fluorinated steroid, an 11beta-hydroxy steroid, a 20-oxo steroid, a 21-hydroxy steroid, a 3-oxo-Delta(4) steroid, a glucocorticoid, a 17alpha-hydroxy steroid, a 16alpha-hydroxy steroid, a C21-steroid hormone, a primary alpha-hydroxy ketone and a tertiary alpha-hydroxy ketone. It derives from a hydride of a pregnane. |
Classification | Small molecule |
Drug class | steroids (not prednisolone derivatives) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |
Identifiers
PDB | — |
CAS-ID | 124-94-7 |
RxCUI | 10759 |
ChEMBL ID | CHEMBL1451 |
ChEBI ID | 9667 |
PubChem CID | 31307 |
DrugBank | DB00620 |
UNII ID | 1ZK20VI6TY (ChemIDplus, GSRS) |
Target
Agency Approved
NR3C1
NR3C1
Organism
Homo sapiens
Gene name
NR3C1
Gene synonyms
GRL
NCBI Gene ID
Protein name
glucocorticoid receptor
Protein synonyms
Nuclear receptor subfamily 3 group C member 1, nuclear receptor subfamily 3 group C member 1 variant hGR-B(54), nuclear receptor subfamily 3 group C member 1 variant hGR-B(77), nuclear receptor subfamily 3 group C member 1 variant hGR-B(93), nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)
Uniprot ID
Mouse ortholog
Nr3c1 (14815)
glucocorticoid receptor (Q61629)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Zilretta - Flexion Therapeutics
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Zilretta - Pacira BioSciences
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 19,555 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
18,098 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more